Press Releases Home - Investor Relations - Press Releases Press Releases Year None2020201920182017201620152014 Date Title November 23, 2020 Corcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of Directors November 18, 2020 U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcept’s U.S. Patent No.10,195,214 November 3, 2020 Corcept Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update October 27, 2020 Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call September 10, 2020 Corcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant to Treat Weight Gain Caused by Antipsychotic Medication August 4, 2020 Corcept Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update July 28, 2020 Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call July 28, 2020 Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing’s Syndrome of Adrenal Origin July 23, 2020 Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian Cancer June 30, 2020 Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 19 Shareholder Tools Email Alerts Print Page RSS Feeds
Press Releases Year None2020201920182017201620152014 Date Title November 23, 2020 Corcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of Directors November 18, 2020 U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcept’s U.S. Patent No.10,195,214 November 3, 2020 Corcept Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update October 27, 2020 Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call September 10, 2020 Corcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant to Treat Weight Gain Caused by Antipsychotic Medication August 4, 2020 Corcept Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update July 28, 2020 Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call July 28, 2020 Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing’s Syndrome of Adrenal Origin July 23, 2020 Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian Cancer June 30, 2020 Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 19